MedPAC Talks Value-Based Healthcare and International Reference Pricing As Aduhelm Cost Sounds Alarms

The Medicare Payment Advisory Commission (MedPAC) is considering a series of measures that would reduce healthcare costs, including international reference pricing and value-based care. Aduhelm’s high price tag was discussed as a potentially wiping out Medicare.

“Congressional Medicare advisers on Thursday (Oct. 7) began discussing policies for controlling drug prices, primarily in Part B, that include setting value-based payments for first-in-class drugs, setting prices for drugs with alternative treatments using reference pricing and changing the provider reimbursement formula in Part B for administering drugs.” Read more here.

(Source: John Wilkerson, Inside Health Policy, 10/7/21)